Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection

• Published in: International journal of molecular sciences Vol. 23; no. 22; p. 14462
• Main Authors: Vulturar, Damiana-Maria, Neag, Maria Adriana, Vesa, Ștefan Cristian, Maierean, Anca-Diana, Gherman, Diana, Buzoianu, Anca Dana, Orăsan, Olga Hilda, Todea, Doina-Adina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.11.2022; MDPI
• Subjects: Antiviral drugs; C-reactive protein; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Ferritin; Humans; Inflammation; Middle East respiratory syndrome; Monoclonal antibodies; Mortality; Oxygen; oxygen support; Patients; Pneumonia; remdesivir; Respiratory diseases; Retrospective Studies; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Superinfection; tocilizumab combination therapy; Viral diseases; Middle East; SARS-CoV-2; tocilizumab combination therapy; remdesivir; oxygen support
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232214462

The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generated many challenges to find an effective drug combination for hospitalized patients with severe forms of coronavirus disease 2019 (COVID-19) pneumonia. We conducted a retrospective cohort study, including 182 patients with severe COVID-19 pneumonia hospitalized between March and October 2021 in a Pneumology Hospital from Cluj-Napoca, Romania. Among patients treated with standard of care, 100 patients received remdesivir (R group) and 82 patients received the combination of remdesivir plus tocilizumab (RT group). We compared the clinical outcomes, the inflammatory markers, superinfections, oxygen requirement, intensive care unit (ICU) admission and mortality rate before drug administration and 7 days after in R group and RT group. Borg score and oxygen support showed an improvement in the R group (p < 0.005). Neutrophiles, C-reactive protein (CRP) and serum ferritin levels decreased significantly in RT group but with a higher rate of superinfection in this group. ICU admission and death did not differ significantly between groups. The combination of remdesivir plus tocilizumab led to a significantly improvement in the inflammatory markers and a decrease in the oxygen requirement. Although the superinfection rate was higher in RT group than in R group, no significant difference was found in the ICU admission and mortality rate between the groups.